tetano
Editor, Senior Moderator
J Biomed Sci
. 2021 Nov 23;28(1):80.
doi: 10.1186/s12929-021-00777-9.
Antibody cocktail effective against variants of SARS-CoV-2
Kang-Hao Liang[SUP] #[/SUP][SUP] 1 2 [/SUP], Pao-Yin Chiang[SUP] #[/SUP][SUP] 1 [/SUP], Shih-Han Ko[SUP] 1 [/SUP], Yu-Chi Chou[SUP] 1 [/SUP], Ruei-Min Lu[SUP] 1 [/SUP], Hsiu-Ting Lin[SUP] 2 [/SUP], Wan-Yu Chen[SUP] 2 [/SUP], Yi-Ling Lin[SUP] 1 3 [/SUP], Mi-Hua Tao[SUP] 1 3 [/SUP], Jia-Tsrong Jan[SUP] 4 [/SUP], Han-Chung Wu[SUP] 5 6 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies.
Methods: We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments.
Results: The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC[SUB]50[/SUB] values (3.35-27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT[SUB]50[/SUB] values 4.93-37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters.
Conclusions: The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta.
Keywords: Cocktail therapy; Neutralizing antibody; Receptor-binding domain (RBD); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. 2021 Nov 23;28(1):80.
doi: 10.1186/s12929-021-00777-9.
Antibody cocktail effective against variants of SARS-CoV-2
Kang-Hao Liang[SUP] #[/SUP][SUP] 1 2 [/SUP], Pao-Yin Chiang[SUP] #[/SUP][SUP] 1 [/SUP], Shih-Han Ko[SUP] 1 [/SUP], Yu-Chi Chou[SUP] 1 [/SUP], Ruei-Min Lu[SUP] 1 [/SUP], Hsiu-Ting Lin[SUP] 2 [/SUP], Wan-Yu Chen[SUP] 2 [/SUP], Yi-Ling Lin[SUP] 1 3 [/SUP], Mi-Hua Tao[SUP] 1 3 [/SUP], Jia-Tsrong Jan[SUP] 4 [/SUP], Han-Chung Wu[SUP] 5 6 [/SUP]
Affiliations
- PMID: 34814920
- DOI: 10.1186/s12929-021-00777-9
Abstract
Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an RNA virus with a high mutation rate. Importantly, several currently circulating SARS-CoV-2 variants are associated with loss of efficacy for both vaccines and neutralizing antibodies.
Methods: We analyzed the binding activity of six highly potent antibodies to the spike proteins of SARS-CoV-2 variants, assessed their neutralizing abilities with pseudovirus and authentic SARS-CoV-2 variants and evaluate efficacy of antibody cocktail in Delta SARS-CoV-2-infected hamster models as prophylactic and post-infection treatments.
Results: The tested RBD-chAbs, except RBD-chAb-25, maintained binding ability to spike proteins from SARS-CoV-2 variants. However, only RBD-chAb-45 and -51 retained neutralizing activities; RBD-chAb-1, -15, -25 and -28 exhibited diminished neutralization for all SARS-CoV-2 variants. Notably, several cocktails of our antibodies showed low IC[SUB]50[/SUB] values (3.35-27.06 ng/ml) against the SARS-CoV-2 variant pseudoviruses including United Kingdom variant B.1.1.7 (Alpha), South Africa variant B.1.351 (Beta), Brazil variant P1 (Gamma), California variant B.1.429 (Epsilon), New York variant B.1.526 (Iota), and India variants, B.1.617.1 (Kappa) and B.1.617.2 (Delta). RBD-chAb-45, and -51 showed PRNT[SUB]50[/SUB] values 4.93-37.54 ng/ml when used as single treatments or in combination with RBD-chAb-15 or -28, according to plaque assays with authentic Alpha, Gamma and Delta SARS-CoV-2 variants. Furthermore, the antibody cocktail of RBD-chAb-15 and -45 exhibited potent prophylactic and therapeutic effects in Delta SARS-CoV-2 variant-infected hamsters.
Conclusions: The cocktail of RBD-chAbs exhibited potent neutralizing activities against SARS-CoV-2 variants. These antibody cocktails are highly promising candidate tools for controlling new SARS-CoV-2 variants, including Delta.
Keywords: Cocktail therapy; Neutralizing antibody; Receptor-binding domain (RBD); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).